Prab: CSV import

2025-02-15T11:06:43Z

CSV import

← Older revision		Revision as of 11:06, 15 February 2025
Line 1:		Line 1:
	~~'''CID16020046''' is a chemical compound~~ with ~~the systematic name 2-~~(~~3,4-dichlorophenyl~~)~~-N-methyl-N-[(1S,2R)-2-(2,4-dichlorophenyl)cyclopropyl]-3-oxo-4-(2-oxoimidazolidin-1-yl)butanamide. It is a synthetic compound that has been studied for its potential pharmacological properties.~~		== Congenital Insensitivity to Pain with Anhidrosis (CIPA) ==

	~~==Chemical Structure==~~		[[File:CID16020046_structure.png\|thumb\|right\|Diagram illustrating the genetic structure associated with CIPA.]]
	~~CID16020046 is a complex organic compound that contains several functional groups~~. ~~The compound has a butanamide backbone,~~ with ~~a 2-oxoimidazolidinyl group at the 4-position, a 3,4-dichlorophenyl group at the 2-position, and a N-methyl-N-[(1S,2R)-2-(2,4-dichlorophenyl)cyclopropyl~~] ~~group at the nitrogen of the amide.~~

	~~==Pharmacological Properties==~~		'''Congenital Insensitivity to Pain with Anhidrosis (CIPA)''', also known as '''Hereditary Sensory and Autonomic Neuropathy Type IV (HSAN IV)''', is a rare [[autosomal recessive]] disorder characterized by the inability to feel pain and temperature, along with decreased or absent sweating (anhidrosis). This condition is caused by mutations in the [[NTRK1]] gene, which is crucial for the development and function of [[nerve cells]] that transmit pain, temperature, and autonomic signals.
	~~While the pharmacological properties of CID16020046 are not fully understood~~, ~~it has been~~ the ~~subject of research due~~ to ~~its potential as a therapeutic agent~~. ~~The compound's activity~~ in ~~biological systems~~ and ~~its interactions with various receptors~~ and ~~enzymes are areas of ongoing study~~.

	==~~Potential Therapeutic Uses~~==		== Clinical Features ==
	The potential therapeutic uses of CID16020046 are currently under investigation. Due to its complex structure and the presence of several functional groups, it is believed that the compound may have a wide range of biological activities. However, further research is needed to fully understand its potential applications in medicine.

	~~==See Also==~~		Individuals with CIPA are unable to perceive pain, which can lead to repeated injuries, burns, and other trauma that go unnoticed. The lack of pain sensation is often accompanied by anhidrosis, which can result in [[hyperthermia]] due to the body's inability to regulate temperature through sweating. Other features may include:
	* [[~~Chemical compound]]~~
	* [[Pharmacology]]
	* [[Therapeutic agent]]

	~~==References==~~		* [[Intellectual disability]]
	~~<references />~~		* [[Self-mutilation]] behaviors
			* [[Joint deformities]] due to repeated injuries
			* [[Infections]] due to unnoticed injuries

	[[Category:~~Chemical Compounds~~]]		== Pathophysiology ==
	[[Category:~~Pharmacology~~]]
	~~{{pharmacology-stub}}~~		CIPA is caused by mutations in the [[NTRK1]] gene, which encodes the [[neurotrophic tyrosine kinase receptor type 1]]. This receptor is essential for the survival and function of [[nociceptive neurons]] and [[sympathetic neurons]]. The absence or dysfunction of these neurons leads to the clinical manifestations of CIPA.
	~~{{No image}}~~
			== Diagnosis ==

			Diagnosis of CIPA is based on clinical evaluation, family history, and genetic testing to identify mutations in the [[NTRK1]] gene. A skin biopsy may show the absence of [[nerve fibers]] responsible for pain and temperature sensation.

			== Management ==

			Management of CIPA focuses on preventing injuries and managing complications. This includes:

			* Regular monitoring for injuries and infections
			* Protective measures to prevent trauma
			* Management of [[hyperthermia]] through environmental control
			* Multidisciplinary care involving [[neurologists]], [[orthopedic surgeons]], and [[psychologists]]

			== Prognosis ==

			The prognosis for individuals with CIPA varies. While the condition itself is not life-threatening, complications from injuries and infections can significantly impact quality of life and life expectancy.

			== Related Pages ==

			* [[Hereditary Sensory and Autonomic Neuropathy]]
			* [[NTRK1]]
			* [[Pain perception]]
			* [[Autosomal recessive disorder]]

			[[Category:Genetic disorders]]
			[[Category:Neurological disorders]]
			[[Category:Rare diseases]]

Prab: CSV import

2025-02-10T09:06:41Z

CSV import

← Older revision		Revision as of 09:06, 10 February 2025
Line 21:		Line 21:
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
	{{pharmacology-stub}}		{{pharmacology-stub}}
			{{No image}}

Prab: CSV import

2024-03-08T14:12:48Z

CSV import

New page

'''CID16020046''' is a chemical compound with the systematic name 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S,2R)-2-(2,4-dichlorophenyl)cyclopropyl]-3-oxo-4-(2-oxoimidazolidin-1-yl)butanamide. It is a synthetic compound that has been studied for its potential pharmacological properties.

==Chemical Structure==
CID16020046 is a complex organic compound that contains several functional groups. The compound has a butanamide backbone, with a 2-oxoimidazolidinyl group at the 4-position, a 3,4-dichlorophenyl group at the 2-position, and a N-methyl-N-[(1S,2R)-2-(2,4-dichlorophenyl)cyclopropyl] group at the nitrogen of the amide.

==Pharmacological Properties==
While the pharmacological properties of CID16020046 are not fully understood, it has been the subject of research due to its potential as a therapeutic agent. The compound's activity in biological systems and its interactions with various receptors and enzymes are areas of ongoing study.

==Potential Therapeutic Uses==
The potential therapeutic uses of CID16020046 are currently under investigation. Due to its complex structure and the presence of several functional groups, it is believed that the compound may have a wide range of biological activities. However, further research is needed to fully understand its potential applications in medicine.

==See Also==
* [[Chemical compound]]
* [[Pharmacology]]
* [[Therapeutic agent]]

==References==
<references />

[[Category:Chemical Compounds]]
[[Category:Pharmacology]]
{{pharmacology-stub}}

CID16020046 - Revision history

Prab: CSV import

Prab: CSV import

Prab: CSV import